Erythromycin A dihydrate
Modify Date: 2024-01-11 15:42:57
Erythromycin A dihydrate structure
|
Common Name | Erythromycin A dihydrate | ||
|---|---|---|---|---|
| CAS Number | 59319-72-1 | Molecular Weight | 751.94200 | |
| Density | N/A | Boiling Point | 818.4ºC at 760 mmHg | |
| Molecular Formula | C37H71NO15 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 448.8ºC | |
Use of Erythromycin A dihydrateErythromycin dihyrate dihydrate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin dihyrate acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1]. |
| Name | erythromycin a dihydrate |
|---|---|
| Synonym | More Synonyms |
| Description | Erythromycin dihyrate dihydrate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin dihyrate acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Erythromycin dihyrate inhibits growth of P. falciparum with IC50 and IC90 values of 58.2 μM and 104.0 μM, respectively[1]. |
| In Vivo | Mice of the ddY strain began to receive Erythromycin dihyrate 7 days after inoculation of EAC cells, and CDF mice begins to receive Erythromycin dihyrate immediately after inoculation of P388 cells[3]. Erythromycin dihyrate (gastric intubation; 0.1-50 mg/kg; 30-120 days) decreases tumor growth from the dose of 5 mg/kg, mice receiving 1-10 mg/kg of Erythromycin dihyrate survives much longer than control mice, Only 10% of mice treated with 5 mg/kg of Erythromycin dihyrate had no evidence of tumor formation on day 60, and the mice are alive even at 120 days after inoculation. However, treatment with 50 mg/kg of Erythromycin dihyrate shortens mean survival time in tumorbearing mice by 4-5 days when it compares to controls[3]. Animal Model: Female ddY mice at the age of 6 weeks with EAC cells or CDF mice at the age of 6 weeks with P388 cells[3] Dosage: 0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg Administration: Gastric intubation; 30-120 days Result: Decreased tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortens the MST in tumorbearing mice. |
| References |
[1]. Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89. [3]. K Hamada, et al. Antitumor Effect of Erythromycin in Mice. Chemotherapy |
| Boiling Point | 818.4ºC at 760 mmHg |
|---|---|
| Molecular Formula | C37H71NO15 |
| Molecular Weight | 751.94200 |
| Flash Point | 448.8ºC |
| Exact Mass | 751.47200 |
| PSA | 203.14000 |
| LogP | 1.72130 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| RTECS | KF4375000 |
|
Thermodynamics of water-solid interactions in crystalline and amorphous pharmaceutical materials.
J. Pharm. Sci. 103(9) , 2772-83, (2014) Pharmaceutical materials, crystalline and amorphous, sorb water from the atmosphere, which affects critical factors in the development of drugs, such as the selection of drug substance crystal form, c... |
| erythromycin a,dihydrate vetranal |